Late-Pregnancy Dysglycemia After Negative Testing for Gestational Diabetes and Risk of the Large-for-Gestational-Age Newborns: A Nest Case-Control Study Based on the Xi’an Longitudinal Mother-Child Cohort Study

Zhangya He¹,²†, Yang Mi³†, Hexiang Yang¹,², Jing Ji¹,²,³, Jiayi Gao¹,²,⁴, Wanyu Zhang¹,²,⁵, Pei Wu¹,², Zhangrui Xu¹,², Shanshan Wang¹,² and Xiaoqin Luo¹,²*

¹ Department of Nutrition and Food Safety, School of Public Health, Xi’an Jiaotong University, Xi’an, China, ² Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi’an, China, ³ Department of Obstetrics and Gynecology, Northwest Women’s and Children’s Hospital, Xi’an, China, ⁴ Emergency Medical Center, Xi’an Public Health Center, Xi’an, China, ⁵ Department of Shaanxi Health Supervision Center, Xi’an, China

Background: The implications of gestational diabetes mellitus (GDM) on the short- and long-term health outcomes of both mother and child have been extensively studied. However, studies related to negative Oral Glucose Tolerance Test (OGTT) results in the second trimester but dysglycemia in late pregnancy on maternal and infant pregnancy outcomes are rare.

Methods: We conducted a nest case-control study within the Xi’an Longitudinal Mother-Child Cohort study (XAMC) to investigate the risk of adverse pregnancy outcomes in mothers and children with maternal negative mid-pregnancy OGTT results but high glycated hemoglobin (HbA1c) levels (≥5.7%) in late pregnancy. All target women who delivered from January 1st, 2017 to December 31st, 2018 in Northwest Women’s and Children’s Hospital in Xi’an were enrolled as the case group (HbA1c ≥ 5.7%). Others with HbA1c < 5.7% but without GDM were selected as the control group (HbA1c < 5.7%) by matching with the same delivery period. The logistic regression models were used to find out the risk factors of adverse pregnancy outcomes in the target population.

Results: A total of 2,116 and 1,907 women were finally enrolled in the case and control groups, respectively. Compared to the control group, more newborns with macrosomia (9.2% vs 4.1%, P < 0.001) and large for gestational age (LGA) (23.7% vs. 13.5%, P < 0.001), but less small for gestational age (SGA) (4.4% vs. 6.1%, P = 0.017) were found in the case group. The differences in other outcomes were not statistically significant. The multiple logistic regression analysis showed that gestational
INTRODUCTION

The prevalence of Gestational diabetes mellitus (GDM) varies from 1 to 20% worldwide and is as high as 14.8% in China (1). Moreover, with the implementation of the comprehensive two-child policy, there has been an increasing trend in recent years. GDM is a common metabolic disease during pregnancy, which increases the risk of short- and long-term complications in pregnant women including pre-eclampsia, cesarean section, miscarriage, and diabetes later in life (2–7). With specific clinical diagnosis and treatment guidelines, GDM is receiving extensive attention from doctors, patients, and society.

Notably, recent studies suggested that the presence of relevant dysglycemia in late pregnancy was associated with a higher rate of macrosomia in their offspring at birth and may contribute to the development of childhood overweight and maternal diabetes in obese mothers with negative Oral Glucose Tolerance Test (OGTT) results (non-GDM) (8, 9). Compared to GDM patients, non-GDM women seem to have a clue of an “all-clear signal,” resulting in reduced attention of doctors and a false sense of security in the mothers. A previous study showed the prevalence of high glycated hemoglobin (HbA1c) levels (≥5.7%) at delivery was about one out of three in non-GDM women in obese pregnant women (9, 10). Although blood glucose is monitored regularly in late pregnancy, few effective measures are taken to control and treat if dysglycemia happened. In addition to the fact that late pregnancy is a period of significant weight gain for pregnant women, making this special group of pregnancies is more prone to metabolic disorders.

Except for the adverse pregnancy outcomes of the mothers, the short- and long-term effects, such as LGA and childhood obesity, of the disorder of blood glucose metabolism during pregnancy on the offspring are also attracting more and more attention from researchers. Epidemically, over 42 million children (<5 years) worldwide were estimated to be overweight or obese (11). A study has pointed out that the high prevalence of childhood obesity and metabolic diseases in adults was closely related to the child's weight status at birth (12). Since the theory of “fetal programming” suggests that adipose tissue and its secretions, mostly influenced by maternal nutrition/malnutrition and dysglycemia during pregnancy, have direct or indirect effects on childhood obesity (13), potentially modifiable factors in the relationship between offsprings childhood overweight and maternal glucose homeostasis are worth exploring.

Therefore, to find out the risk of offspring overweight at birth in non-GDM women with dysglycemia in late pregnancy, we conducted a nest case-control study in the Xi’an longitudinal mother-child cohort study (XAMC) by using a unique set of longitudinal data of mothers and their newborns. The finding of our study is of particular relevance to proposing effective intervention and prevention measures in the target population and would provide more evidence for blood glucose management throughout pregnancy.

METHODS

Study Population

XAMC is an ongoing prospective cohort study designed to investigate the effects of early intrauterine exposure on mothers and their offspring outcomes in Xi’an, China. Briefly, XAMC recruited women during early pregnancy at Northwest Women’s and Children’s Hospital (NWCH), the most extensive obstetrics and gynecology hospital in northwestern China, with 20,000–30,000 deliveries per year (14). In this study, all pregnant women with negative OGTT results in the second trimester who delivered from January 1st, 2017 to December 31st, 2018 were selected as the study population. Women who had a singleton live birth with over 28 weeks gestational age, and had GDM testing data (75-g OGTT according to the IADPSG recommendation) (15) between 24 and 28 weeks of gestation and HbA1c data during the late pregnancy were eligible to be included in the analysis. The details of sample size calculation process was provided in the Supplementary Material. The study was approved by both the Research Ethics Committees of NWCH (NWCH2012-013) and Xi’an Jiaotong University (XJTU2016-053). Written consent was obtained from participants.

Grouping

Blood glucose concentrations were obtained from the hospital medical data system. According to the hospital’s usual protocol of assessment of blood glucose in antenatal periods, all pregnant women who met the inclusion criteria had performed an OGTT test (including FPG) in mid-pregnancy (24–28 weeks) and had an HbA1c test at delivery. Details of the OGTT and HbA1c testing are available in the previously reported literature (8). Women with negative OGTT results were assigned to two groups according to the HbA1c levels during late pregnancy. The case group had a sign of dysglycemia with HbA1c ≥ 5.7%. Others with HbA1c < 5.7% matched with the delivery period of the case group were selected as the control group (9). GDM testing was defined as negative when none, and positive when 1 or more, of the 3 glucose concentrations of a 75-g OGTT met or exceeded the reference values according to the IADPSG criteria: fasting glucose ≥ 5.1 mmol/l, 1-h post-load glucose ≥ 10 mmol/l, or 2-h glucose ≥ 8.6 mmol/l. The average delivery weight was 3,400 g, with a 2.5% rate of macrosomia. The average newborn birth weight was 3,310 g, with a 1.6% rate of LGA.

Conclusion: The glycemic management during the late pregnancy of non-GDM women should be given special consideration to reduce the risk of overweight offspring at birth.

Keywords: GDM, dysglycemia, cohort, obesity, children
post-load glucose ≥ 8.5 mmol/l (15). The term “late-pregnancy
dysglycemia” was used when the maternal HbA1c value during the
late pregnancy was greater than or equal to the cut-off of 5.7%
(39 mmol/mol) (8).

Outcomes Variables
Maternal pregnancy outcomes included lateral episiotomy,
cesarean section, and postpartum bleeding. Information on
maternal primiparity, history of adverse pregnancy, education
level, family history of the disease, complications during pregnancy, maternal HbA1c in late pregnancy were extracted
from the mothers’ pregnancy records. Pre-conception BMI was
reported by the woman at this first visit and documented in the
pregnancy record booklet. Total gestational weight gain (GWG)
in pregnancy was defined as the difference between the weight
at delivery and pre-conception weight. The child’s characteristics,
such as sex, length, weight, gestational age, APGAR score were
collected at birth. Macrosomia defined as birth weight ≥ 4,000 g
and large-for-gestational-age (LGA) defined as birth weight >90th percentile of the mean weight for the same gestational
age (16). Meanwhile, the small-for-gestational-age (SGA ) was
defined when birth weight was below the 10th percentile of the
mean weight for the same gestational age.

Statistical Analysis
Continuous variables were summarized as means ± SDs if
normally distributed and medians with IQRs if not normally
distributed. Differences in characteristics between the two
groups were assessed by a Student’s t-test (normal distribution) or
Mann-Whitney U test (non-normal distribution) for continuous
variables, and a Chi-square test for categorical variables. Risk
factors were analyzed using logistic analysis. Adjustments were
made for potential confounding variables, including family
history of diabetes, mode of delivery, height, pre-pregnancy
weight, weight gain during pregnancy, prenatal weight, gestational
age, newborn length, and prenatal triglycerides. Analyses were carried out using SPSS statistical software (version
24) (SPSS Inc., Chicago, USA). Significance was defined as $P < 0.05$ (two-tailed).

RESULTS
Basic Characteristics of Participants
There were 47,942 mother-child pairs during the study period
and almost 85% (40,750) of them had negative OGTT results
at mid-pregnancy. Finally, 39,745 met the inclusion criteria.
Among them, there were a total of 2,116 (5.32%) pairs with
HbA1c ≥ 5.7% (the case group), and 1,907 pairs with HbA1c < 5.7% (the control group, which matched the same delivery
period) (Figure 1). All mothers involved in this study did not
develop any obvious symptoms related to diabetes throughout
pregnancy, even diabetes requiring insulin therapy or any clinical
symptoms of insulin resistance, like acanthosis nigricans. As shown in Table 1, compared to the control group, the case group
had a higher advanced age (16.9% vs. 14.4%, $P = 0.03$), a lower
education level (13.3% vs. 16.5%, $P = 0.014$), higher proportions
of family history of diabetes (7% vs. 4.8%, $P = 0.014$), anemia
(51.8% vs. 42.7%, $P < 0.001$) and overweight and obese before
pregnancy (13.6% vs. 9%, $P < 0.001$), and more gestational
weight gain (GWG). Other characteristics of participants, such as
parity, history of adverse pregnancy, other complications during pregnancy and biochemical indicators of lipid metabolism were comparable between the two groups. Moreover, the distribution characteristics of the offspring presented in Table 2 showed that the newborns were heavier ($3434.08 \pm 440.26$ vs. $3322.66 \pm 456.72$, $P < 0.001$) and had a longer birth length ($50.31 \pm 0.97$
vs. $50.06 \pm 2.06$, $P < 0.001$) in the case group compared with the
control group.

Associations Between HbA1c Values at Late Pregnancy and Pregnancy Outcomes
As shown in Table 3, the differences of the incidence of adverse pregnancy outcomes for mothers and some of the adverse
birth outcomes for children between the two groups were not
statistically significant, including lateral episiotomy (7% vs. 4.8%, $P = 0.068$), postpartum bleeding (0.9% vs. 1%, $P = 0.869$),
and cesarean section (41.4% vs. 41.2%, $P = 0.904$) for mothers, while
birth defects (0.3% vs. 0.1%, $P = 0.085$), prematurity (4.8% vs.
4.9%, $P = 0.878$), perinatal mortality (0.3% vs. 0.3%, $P = 0.857$),
and fetal distress (1.9% vs. 2.6%, $P = 0.145$) in the offspring.
However, there was a remarkable higher prevalence of LGA
(23.7% vs. 15.3%, $P < 0.001$) and macrosomia (9.2% vs. 4.1%, $P < 0.001$) in the offspring of the case group.

The univariate logistical analysis with the occurrence of LGA and/or macrosomia as an arbitrary adverse pregnancy outcome (Table 4) showed that HbA1c ≥5.7%, pre-conception

![Flow diagram outlining the selection of the study population.](image-url)
### TABLE 1 | Basic characteristics of participants according to late pregnancy HbA1c categories.

| Characteristics                          | Case group (n = 2,116) | Control group (n = 1,907) | $x^2/t$  | P     |
|-----------------------------------------|------------------------|---------------------------|----------|-------|
| Age at conception, years, n (%)        |                        |                           |          |       |
| ≥35                                     | 358 (16.9)             | 275 (14.4)                | 4.721    | 0.030 |
| <35                                     | 1,758 (83.1)           | 1,632 (85.6)              |          |       |
| Education level, n (%)                  |                        |                           |          |       |
| High School and below                   | 282 (13.3)             | 314 (16.5)                |          |       |
| College degree                          | 1,500 (70.9)           | 1,320 (69.2)              |          |       |
| Postgraduate and above                  | 334 (15.8)             | 273 (14.3)                |          |       |
| Family history of diabetes, n (%)       | 148 (7)                | 91 (4.8)                  |          |       |
| Family history of hypertension, n (%)   | 320 (15.1)             | 262 (13.7)                |          |       |
| Pre-conception BMI (kg/m²), n (%)       |                        |                           |          |       |
| <18.5                                   | 220 (10.4)             | 324 (17)                  | 51.683   | <0.001|
| 18.5–24.9                               | 1,809 (76)             | 1,411 (74)                |          |       |
| 25.0–29.9                               | 249 (11.8)             | 154 (8.1)                 |          |       |
| ≥30.0                                   | 38 (1.8)               | 18 (0.9)                  |          |       |
| Total GWG (kg)*                         |                        |                           |          |       |
| <18.5                                   | 17.00 ± 4.26           | 15.45 ± 4.18              | 4.209    | <0.001|
| 18.5–24.9                               | 16.16 ± 4.39           | 15.17 ± 4.09              | 6.359    | <0.001|
| 25.0–29.9                               | 14.47 ± 4.92           | 12.90 ± 5.06              | 3.072    | 0.002 |
| ≥30.0                                   | 12.03 ± 4.78           | 11.83 ± 4.00              | 0.148    | 0.883 |
| Parity, n (%)                           |                        |                           |          |       |
| Nulliparous                             | 1,453 (68.7)           | 1,288 (67.5)              | 2.037    | 0.361 |
| Multiparous                             | 663 (31.3)             | 619 (32.5)                |          |       |
| History of adverse pregnancy, n (%)     | 879 (41.5)             | 806 (42.4)                | 0.283    | 0.594 |
| Complications during pregnancy, n (%)   |                        |                           |          |       |
| Abnormal thyroid function               | 171 (8.1)              | 152 (8)                   | 0.017    | 0.897 |
| Anemia                                  | 1,097 (51.8)           | 814 (42.7)                | 33.736   | <0.001|
| Hypertension                            | 43 (2)                 | 29 (1.5)                  | 1.493    | 0.222 |
| Biochemical indicators in late pregnancy birth |                  |                           |          |       |
| TC (mmol/mol)                           | 5.76 ± 1.06            | 5.75 ± 0.92               | 0.278    | 0.781 |
| TG (mmol/mol)                           | 3.01 ± 1.06            | 2.96 ± 1.01               | 1.447    | 0.148 |
| HDL (mmol/mol)                          | 1.72 ± 0.32            | 1.74 ± 0.35               | −1.732   | 0.083 |
| LDL (mmol/mol)                          | 3.01 ± 1.06            | 3.00 ± 0.63               | 0.358    | 0.721 |
| HbA1c level (%)                         | 5.85 ± 0.19            | 5.11 ± 0.33               | 85.135   | <0.001|

Continuous variables meet the conditions of normality, and categorical variables are expressed as mean ± standard deviation and counts (percentages). Separately. And the t-test and chi-square test were used to analyze the differences between groups. P-values < 0.05 were considered statistically significant. GWG, gestational weight gain; TC, total cholesterol; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; HbA1c, glycated hemoglobin. *means total gestational weight gain by pre-conception BMI.

BMI < 18.5, prematurity, maternal height, pre-pregnancy weight, GWG, prenatal weight, gestational age, neonatal length at birth, late pregnancy HbA1c, and TG were associated with offspring overweight. Further multifactorial logistical analysis indicated that gestational age (OR = 1.644, 95% CI, 1.413–1.914), fetal length (OR = 7.309, 95% CI, 5.774–9.252), prenatal TG (OR = 1.159, 95% CI, 1.019–1.318), and late pregnancy HbA1c (OR = 2.063, 95% CI, 1.077–3.952) were risk factors for offspring overweight. The association between late-pregnancy HbA1c levels and offspring overweight remained after adjusting for family history of diabetes, mode of delivery, height, pre-pregnancy weight, GWG, prenatal weight, gestational age, fetal length, and maternal TG. The risk of offspring being overweight increased to 2.516 (95% CI, 1.692–3.739) times in the case group.

**DISCUSSION**

In China, the occurrence of dysglycemia in the last trimester of pregnancy despite prior negative testing for GDM and its consequences have not been extensively concerned. Although it would increase the risk of both short- and long-term adverse outcomes for both mothers and children, no guideline for routine monitoring was available clinically. In the present
study, we found that intrauterine exposure to late-pregnancy dysglycemia even without GDM is strongly associated with offspring overweight. Our large population-based cohort study provides novel evidence that glycemic management during the late pregnancy of non-GDM women also should be considered to reduce the risk of overweight offspring in early life.

Numerous studies showed that the intrauterine environment impacted early life from conception to the toddler years (the first 1,000 days), even influencing a person’s response to later exposures and subsequently modifying their health and disease risk later in life (17–19). Apart from genetic background and lifestyle factors related to maternal obesity, prenatal metabolic influences of a high glucose intrauterine environment seem to play an important role in the offspring being overweight at birth (11, 20). Although the study found that about half of births of women with diabetes were LGA (21), the situation in non-GDM women with glucose metabolism disorders in the third trimester is unclear. A German study recently showed that obese, GDM-negative women with late-pregnancy dysglycemia had higher proportions of offspring with LGA birth weight than those without. Moreover, the offspring of these women had greater weight gain during early childhood (8). Similarly, we also found more women were overweight/obese before conception in that than the target population, and there was a remarkable higher prevalence of LGA (23.7% vs. 15.3%, P < 0.001) and macrosomia (9.2% vs. 4.1%, P < 0.001) in their offspring. Although the prevalence of late-pregnancy dysglycemia in non-GDM population was around 5% in our study, the absolute number was quite large. Most importantly, the prevalence of macrosomia was 9.2% and LGA was 23.7%. The high prevalence

### TABLE 2 | Newborn offspring characteristics of participants according to late pregnancy blood glucose among the total participants.

| Characteristics                  | Case group (n = 2,116) | Control group (n = 1,907) | x²/t | P   |
|----------------------------------|------------------------|---------------------------|------|-----|
| Sex                              |                        |                           |      |     |
| Male                             | 1,184 (56)             | 886 (51.7)                | 9.325| 0.009|
| Female                           | 932 (44)               | 919 (49.2)                |      |     |
| Birth weight, g                  | 3434.08 ± 440.26       | 3322.66 ± 456.72          | 7.874| <0.001|
| Gestational age, weeks           | 39.42 ± 1.47           | 39.41 ± 1.57              | 0.289| 0.772|
| Birth length, cm                 | 50.31 ± 0.97           | 50.06 ± 2.06              | 4.913| <0.001|
| Apgar score                      |                        |                           |      |     |
| Apgar-1 min                      | 8.97 ± 0.28            | 8.96 ± 0.40               | 1.139| 0.255|
| Apgar-5 min                      | 9.98 ± 0.25            | 9.96 ± 0.42               | 1.596| 0.111|
| Apgar-10 min                     | 9.98 ± 0.35            | 9.97 ± 0.39               | 0.419| 0.675|

Continuous variables meet the conditions of normality and categorical variables are expressed as mean ± standard deviation and counts (percentages). Separately. And the t-test and chi-square test were used to analyze the differences between groups. P-values <0.05 were considered statistically significant. HbA₁c, glycated hemoglobin.

### TABLE 3 | Adverse outcomes of participants and offspring according to late pregnancy blood glucose among the total participants.

| Adverse outcomes          | Case group (n = 2,116) | Control group (n = 1,907) | x²/t | P   |
|---------------------------|------------------------|---------------------------|------|-----|
| Maternal outcomes         |                        |                           |      |     |
| Lateral Episiotomy        | 453 (21.4)             | 364 (19.1)                | 3.338| 0.068|
| Postpartum bleeding       | 20 (0.9)               | 19 (1)                    | 0.027| 0.869|
| Cesarean section          | 875 (41.4)             | 785 (41.2)                | 0.015| 0.904|
| Children outcomes         |                        |                           |      |     |
| Birth defects             | 7 (0.3)                | 1 (0.1)                   | 3.917| 0.085|
| Prematurity               | 101 (4.8)              | 93 (4.9)                  | 0.023| 0.878|
| Macrosomia                | 195 (9.2)              | 78 (4.1)                  | 41.655| <0.001|
| Perinatal mortality       | 6 (0.3)                | 6 (0.3)                   | 0.033| 0.857|
| SGA                       | 94 (4.4)               | 117 (6.1)                 | 5.785| 0.017|
| LGA                       | 501 (23.7)             | 291 (15.3)                | 44.946| <0.001|
| Fetal distress            | 40 (1.9)               | 49 (2.6)                  | 2.138| 0.145|

Categorical variables are expressed as counts (percentages). And the t-test and chi-square test were used to analyze the differences between groups. P-values <0.05 were considered statistically significant.

SGA, small for gestational age; LGA, large for gestational age. HbA₁c, glycated hemoglobin.
### TABLE 4 | Univariate and Multivariate analysis of related factors of offspring macrosomia and LGA.

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|-----------------------|
|           | OR (95% CI)         | P-value               | Offspring overweight-adjusted Risk Ratio (95% CI) | OR (95% CI) | P-value |
| Gestational age, week | 1.827 (1.612–2.072) | <0.001 | 1.644 (1.413–1.914) | <0.001 |
| Fetal length, cm | 3.828 (3.340–4.387) | <0.001 | 7.039 (5.774–9.252) | <0.001 |
| TG (mmol/mol) | 1.214 (1.099–1.340) | <0.001 | 1.159 (1.019–1.318) | 0.025 |
| Prenatal HbA1c | 2.479 (1.806–3.402) | <0.001 | 2.063 (1.077–3.952) | 0.029 |
| Pre-conception BMI (kg/m²) | | | | |
| <18.5 | 0.379 (0.218–0.656) | 0.001 | | |
| 18.5–23.9 | Ref | | | |
| 24–27.9 | 1.406 (0.968–2.030) | 0.072 | | |
| ≥28 | 0.811 (0.251–2.619) | 0.726 | | |
| Prematurity | 0.074 (0.010–0.534) | 0.01 | | |
| Prenatal weight, kg | 1.061 (1.061–2.072) | <0.001 | | |

A binary Logistic analysis was used to analyze the effect of late pregnancy HbA1c on neonatal birth weight overweight, adjusting for confounding factors such as the family history of diabetes, pre-pregnancy weight, weight gain during pregnancy, and fetal sex and length at birth. TG, Triglycerides; HbA1c, glycated hemoglobin; OR, odds ratio; CI, confidence interval.

1 Model 1 Adjusted for family history of diabetes, mode of delivery, height.
2 Model 2 Adjusted for family history of diabetes, mode of delivery, height, pre-pregnancy weight, weight gain during pregnancy, prenatal weight.
3 Model 3 Adjusted for family history of diabetes, mode of delivery, height, pre-pregnancy weight, weight gain during pregnancy, prenatal weight, gestational age, newborn length, prenatal triglycerides.
of childhood obesity and metabolic diseases in adults was closely related to the child's weight status at birth (12). LGA neonates have the highest BMI at age 4–7 years (22), putting them at a higher lifetime risk of being overweight and developing obesity and metabolic diseases (23). A negative GDM test at the end of the second trimester was not an “all-clear signal” and did not result in reduced attention from caregivers and a false sense of security in mothers, especially those who are overweight/obese.

It is already widely known that women with GDM not only increased the incidence of stillbirths and birth complications, including a high risk of cesarean delivery, shoulder dystocia, birth injury, and macrosomia (24–26) but also increased the risk of developing T2DM in subsequent years (3–5). But in our study, the difference in adverse pregnancy outcomes between mothers with metabolic disorders in the case and control group was not statistically significant. This may be related to the fact that the population included in our study were non-GDM which indicated that the sustained stability of maternal metabolism in the early and middle stages of pregnancy, the critical period of fetal development, lays a good foundation for a portion of pregnancy outcomes. In addition, our inclusion criteria were only live fetuses older than 28 weeks of gestational age were included, which reduced the possibility of the occurrence of severe adverse pregnancy outcomes such as stillbirths and malformed fetuses. As the cohort progresses successfully, we will continue to monitor and report on the long-term health outcomes of mothers and children.

One of the major strengths of our study was related to the large contemporary mother-child XAMC cohort, which is unique in the size of the population of mothers and the availability of trimester-specific data, including HbA1c at late pregnancy as a marker of glycemic control in late pregnancy. Secondly, this is the first time to find out the risk of offspring related to the child's weight status at birth (27). Measures of glycaemic variation throughout the pregnancy cycle has significant public health implications for reducing childhood obesity. The third strength of our study was that outcomes data were ascertained by trained medical staff, and pregnancy and postpartum confounding factors associated with adverse pregnancy outcomes and neonatal macrosomia were comprehensively collected and adjusted for pregnancy complications, pre-pregnancy body mass, and pregnancy weight gain.

However, some limitations of our study have to be considered. Firstly, we only take HbA1c levels into consideration for late pregnancy dysglycemia. Despite a general agreement that maternal late hyperglycemia causing fetal hyperinsulinemia is an important determinant of fetal macrosomia, there is some evidence that the contribution of maternal hyperglycemia to the variance in LGA birth weight is relatively low, and even high rates of LGA birthweight are reported despite apparently normal HbA1c levels (27–29). Measures of glycaemic variation using newer methods, such as continuous glucose monitoring, may contribute to a better understanding of the relationship between hyperglycemia and fetal macrosomia in the future (29).

In any case, continuous monitoring of the mother's blood glucose during pregnancy, even those with a negative OGTT test in mid-pregnancy, will reduce the risk of childhood obesity and even metabolic diseases in the future. Secondly, GWG during the 2nd and 3rd trimesters and its correlation with HbA1c will help to understand the dynamics of late trimester dysglycemia on the fetal weight, but this variable was not collected before in this retrospective cohort. However, up to 90% of pregnant women experience nausea and vomiting, and even weight loss in the first trimester (30–32), so the majority of GWG is accounted for by weight gain in the 2nd and 3rd trimesters. And in an analysis study, we found that even after adjusting for GWG, there still was a relationship between HbA1c levels at birth and LGA newborns (Table 4). Last but not least, this is a cross-sectional presentation of the basic information of an ongoing cohort study, and the causality argument is not strong enough, and further follow-up of long-term health outcomes of mothers and children in this specific population is needed in the future.

CONCLUSION

The third-trimester HbA1c levels were the important potentially modifiable predictors of birthweight, reinforcing the need for careful glucose control throughout pregnancy. In future studies, more sensitive measures of both glucose control and fetal growth and body composition should be used to explore critical windows for the effect of maternal blood glucose concentration on birthweight.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The study was approved by both the Research Ethics Committees of NWCH (NWCH2012-013) and Xi’an Jiaotong University (XJTU2016-053). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

ZH and XL designed the study and wrote the manuscript. ZH and YM performed the analysis and quality control on the data. JG, HY, WZ, PW, JJ, ZX, SW, and YM collected the data. XL had primary responsibility for the final content, is the guarantor of this work and, as such, have full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. ZH, YM, HY, JG, JJ, WZ, PW, ZX, SW, and XL read and approved the final manuscript and contributed to revising the manuscript critically for important
intellectual content. All authors contributed to the article and approved the submitted version.

FUNDING
This research was funded by the National Natural Science Foundation of China (No. 81874263) and the Key Special Project of the Development Center for Medical Science & Technology of the National Health Commission of the People’s Republic of China (W2015CAE060).

REFERENCES
1. Gao C, Sun X, Lu L, Liu F, Yuan J. Prevalence of gestational diabetes mellitus in mainland China: a systematic review and meta-analysis. J Diabetes Invest. (2019) 10:154–62. doi: 10.1111/jdi.12854
2. Lowe WL Jr, Scholtens DM, Lowe LP, Kuang A, Nodzenski M, et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. JAMA. (2018) 320:1005–16. doi: 10.1001/jama.2018.11628
3. O’Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes. (1964) 13:278–85.
4. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes – a systematic review. Diabetes Care. (2002) 25:1862–8. doi: 10.2337/diacare.25.10.1862
5. Metzger BE. Long-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring. Clin Obstet Gynecol. (2007) 50:972–9. doi: 10.1097/GFRE.0b013e31815a61d6
6. Schmidt CB, Voorhorst I, van de Gaar VHW, Keukens A, van Loon BJP, Snoek Fj, et al. Diabetes distress is associated with adverse pregnancy outcomes in women with gestational diabetes: a prospective cohort study. BMC Preg Child. (2019) 19:223. doi: 10.1186/s12884-019-2376-6
7. Perna R, Loughan AR, Le J, Loughan AR, Le J, Tyson K. Gestational diabetes: long-term central nervous system development and cognitive sequelae. Appl Neuropsychol Child. (2015) 4:217–20. doi: 10.1080/21622965.2013.874951
8. Gomes D, von Kries R, Delius M, Mansmann U, Nast M, Schubert M, et al. Late-pregnancy dysglycemia in obese pregnancies after negative testing for gestational diabetes and risk of future childhood overweight: an interim analysis from a longitudinal mother-child cohort study. PLoS Med. (2018) 15:e1002681. doi: 10.1371/journal.pmed.1002681
9. Ensenauer R, Brandlhuber L, Burgmann M, Sobotzki C, Zwaifink C, Anzill S, et al. Obese nondiabetic pregnancies and high maternal glycated hemoglobin at delivery as an indicator of offspring and maternal parturition risks: the prospective peaches mother-child cohort study. Clin Chem. (2015) 61:1381–90. doi: 10.1373/clinchem.2015.242206
10. Ensenauer R, Grmachi J, Nehring L, von Kries R. Increased hemoglobin A1c in obese pregnant women after exclusion of gestational diabetes. Clin Chem. (2012) 58:1152–4. doi: 10.1373/clinchem.2011.181446
11. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. (2014) 384:766–81. doi: 10.1016/S0140-6736(14)60460-8
12. Pringle KG, Lee YQ, Weatherall L, Keogh L, Diehm C, Roberts CT, et al. Influence of maternal adiposity, preterm birth and birth weight centiles on early childhood obesity in an Indigenous Australian pregnancy-through-to-early-childhood cohort study. J Dev Orig Hlth Dis. (2019) 10:39–47. doi: 10.1111/jdo.12003
13. Kiess W, Petzold S, Topfer M, Garten A, Bluhser S, Kapellen T, et al. Adipocytes and adipose tissue. Best Pract Res Clin En. (2008) 22:135–50. doi: 10.1016/j.berm.2007.10.002
14. Ji J, He ZY, Qu PF, Gao JY, Zhang WY, Wu P, et al. The Xi’an longitudinal mother-child cohort study: design, study population, and methods. Eur J Epidemiol. (2021) 36:223–32. doi: 10.1007/s10654-020-00704-6
15. Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. (2010) 33:676–82. doi: 10.2337/dc10-0719
16. Voigt M, Schneider KT, Jahrig K. [Analysis of a 1992 birth sample in Germany, 1: New percentile values of the body weight of newborn infants]. Geburtshilfe Frauenheilkd. (1996) 56:550–8. doi: 10.1055/s-2007-102388
17. Falkner B. Maternal and gestational influences on childhood blood pressure. Pediatr Nephrol. (2020) 35:1409–18. doi: 10.1007/s00467-019-4201-x
18. Robertson RC, Manges AR, Finlay BB, Prendergast AJ. The human microbiome and child growth - first 1000 days and beyond. Trends Microbiol. (2019) 27:131–47. doi: 10.1016/j.tim.2018.09.008
19. Schwarzenberg SJ, Georgeff MK, Committee On N. Advocacy for improving nutrition in the first 1000 days to support childhood development and adult health. Pediatrics. (2018) 141:6e20173716. doi: 10.1542/peds.2017-3716
20. Schafer-Graf UM, Graf K, Kullbacka I, Kjos SL, Dudenhausen J, Vetter K, et al. Maternal lipids as strong determinants of fetal environment and growth in pregnancies with gestational diabetes mellitus. Diabetes Care. (2008) 31:1858–63. doi: 10.2337/dc07-0039
21. Yang J, Cummings EA, O’Connell C, Jangaard K. Fetal and neonatal outcomes of diabetic pregnancies. Obstet Gynecol. (2006) 108:644–50. doi: 10.1097/00006251-200608080-00027
22. Vohr BR, McGarvey ST, Tucker R. Effects of maternal gestational diabetes on offspring adiposity at 4-7 years of age. Diabetes Care. (1999) 22:1284–91. doi: 10.2337/diacare.22.8.1284
23. Zhang S, Wang L, Leng I, Liu H, Li W, Zhang T, et al. Hypertensive disorders of pregnancy in women with gestational diabetes mellitus on overweight status of their children. J Hum Hypertens. (2017) 31:731–6. doi: 10.1038/jhh.2017.17
24. Starikov R, Dudley D, Reddy UM. Stillbirth in the pregnancy complicated by diabetes. Curr Diabetes Rep. (2015) 15:11. doi: 10.1007/s11892-015-0580-y
25. Metzger BE, Coustan DR, Trimble ER. Hyperglycemia and adverse pregnancy outcomes. Clin Chem. (2019) 65:937–8. doi: 10.1373/clinchem.2019.303990
26. Wendland EM, Torloni MR, Falavigna M, Trujillo J, Dode MA, Campos MA, et al. Gestational diabetes and pregnancy outcomes - a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Preg Child. (2012) 12:23. doi: 10.1186/1471-2393-12-23
27. Evers IM, de Valk HW, Mol BWJ, ter Braak EWM, Visser GHA. Macromasia despite good glycaemic control in Type I diabetic pregnancy; results of a nationwide study in The Netherlands. Diabetologia. (2002) 45:1484–9. doi: 10.1007/s00125-002-0958-7
28. Iberpca J, Taupin P, Dubois-Laforgue D, Duranteau L, Lahlou N, Boitard C, et al. Heterogeneity of fetal growth in type 1 diabetic pregnancy. Diabetes Metab. (2001) 27:339–44.
29. Kerssen A, de Valk HW, Visser GHA. Increased second-trimester maternal glucose levels are related to extremely large-for-gestational-age infants in women with type 1 diabetes. Diabetes Care. (2007) 30:1069–74. doi: 10.2337/dc06-1985
30. Buskens M, Venkataraman R, Caritis S. Nausea and vomiting of pregnancy - what's new? Auton Neurosci. (2017) 202:62–72. doi: 10.1016/j.autneu.2016.05.002
31. Festin M. Nausea and vomiting in early pregnancy. BMJ Clin Evid. (2014) 2014.

ACKNOWLEDGMENTS
We thank the clinical staff of Northwest Women’s and Children’s Hospital for their contributions to this study.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2022.829706/full#supplementary-material
32. Emelianova S, Mazzotta P, Einarson A, Koren G. Prevalence and severity of nausea and vomiting of pregnancy and effect of vitamin supplementation. Clin Invest Med. (1999) 22:106–10.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.